PANANGIN® Solution 10 ml, 5 ampoules
- $10.70
Out Of Stock
The instruction for medical use
of PANANGIN® medicine
the Trade name
of Panangin®
the International unlicensed name
Is not present
the Dosage form
the Concentrate for preparation of solution for infusions, 10 ml
Structure
One ampoule contains
active agents: magnesium asparaginate of 400.00 mg
(in the form of magnesium of asparaginate of tetrahydrate of 499.80 mg)
potassium asparaginate of 452.00 mg
(in the form of potassium of asparaginate of the gemigidrat of 475.73 mg),
excipients: potassium hydroxide, 10% solution, water for injections.
Description
Transparent, colourless or slightly greenish solution.
Pharmacotherapeutic group
Mineral additives. Other mineral substances.
The ATX A12CX code
the Pharmacological
Pharmacodynamics Ions properties of potassium and magnesium as important intracellular cations get into gear of a number of enzymes, into process of linking of macromolecules with subtsellulyarny elements and into the mechanism of muscular contraction at molecular level. The ratio out of - and intracellular concentration of potassium ions, calcium, sodium and magnesium influences sokratitelny ability of a myocardium. Aspartate as endogenous substance is a carrier of potassium ions and magnesium, has the significant affinity to cells, its salts are exposed to dissociation only in insignificant degree. Thereof ions get into intracellular space in the form of complex connections. Magnesium and potassium aspartate improve metabolism of a myocardium. Insufficient content of potassium and magnesium in an organism increases risk of developing arterial hypertension, atherosclerotic defeat of coronary vessels, disturbances of a heart rhythm, myocardium pathology.
Indications
- for additional therapy in chronic heart diseases (in heart failure, during the postinfraktny period)
- disturbances of a warm rhythm, mainly ventricular arrhythmias
- in a combination with foxglove drugs
the Route of administration and doses
Drug is intended only for intravenous administration. 1-2 ampoules in 5% solution of glucose apply contents to this purpose and enter in the form of intravenous infusion slowly, by drop infusion. If necessary the dose can be repeated in 4-6 hours. Duration of therapy is established individually.
Drug is suitable for combination therapy.
The maximum single dose — 2 ampoules (20 ml) of Panangina®, in case of need perhaps repeated introduction in 4-6 h.
The maximum daily dose – 4 ampoules (40 ml) of Panangina®.
Use in pediatrics
there Are no data on safety and efficiency of medicine at children and teenagers up to 18 years.
Side effects
- emergence of symptoms of a hyperpotassemia / gipermagniyemii at fast administration of drug (the description of symptoms see in the section Overdose)
Contraindications
- sharp and chronic kidney disease
- Addison's disease
- atrioventricular block of the III degree, cardiogenic shock (the ABP & lt, 90
mm Hg)
- the expressed hyperpotassemia
- hypersensitivity to drug components
Medicinal interactions
At simultaneous use of Panangina® with kaliysberegayushchy diuretics and/or APF inhibitors perhaps development of a hyperpotassemia.
Special instructions
Fast administration of drug can cause hyperaemia of the person. It is necessary to be careful when prescribing drug the patient with the diseases which are followed by a hyperpotassemia. At this category of patients it is regularly recommended to investigate concentration of electrolytes in a syvrotka of blood.
Pregnancy and a lactation
use of the drug Panangin® at pregnancy and in the period of a lactation according to indications is possible.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
during use of drug needs to be careful at
control of vehicles or other potentially dangerous mechanisms.
Overdose
At long-term use of drug the cases of overdose were not registered.
Hyperpotassemia symptoms: fatigue, muscle weakness, paresthesias, confusion of consciousness, disorder of function of heart (bradycardia, atrioventricular block, arrhythmia, cardiac arrest)
gipermagniyemiya Symptoms: decrease in neuromuscular excitability, nausea, vomiting, drowsiness, decrease in the ABP. At sharp increase in concentration of an ion of magnesium of blood: oppression of deep tendon jerks, paralysis of breath, lump.
Treatment: drug withdrawal, symptomatic therapy (administration of solution of Calcii chloridum intravenously in a dose of 100 mg/min., in case of need - a hemodialysis).
A form of release and packing
On 10 ml of drug in ampoules from colourless glass with a point for a break.
On 5 ampoules place in plastic blister strip packaging.
On 1 blister strip packaging together with the instruction for medical use in the state and Russian languages place in a box of cardboard.
To Store storage conditions at a temperature from 15 °C to 30 °C.
To store out of children's reach!
3 years
not to use a period of storage after expiry date.
Prescription status
According to the prescription
the Name and the country
of the JSC Gideon Richter manufacturing organization,
1103 Budapest, Dyomryoi St., 19-21, Hungary
the Name and the country of the owner of the registration certificate
of JSC Gideon Richter, Hungary
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products:
Representative office of JSC Gideon Richter in RK
E-mail: info@richter.kz
Phone number: 8-(727) 258-26-22, 8-(727) 258-26-23
of PANANGIN® medicine
the Trade name
of Panangin®
the International unlicensed name
Is not present
the Dosage form
the Concentrate for preparation of solution for infusions, 10 ml
Structure
One ampoule contains
active agents: magnesium asparaginate of 400.00 mg
(in the form of magnesium of asparaginate of tetrahydrate of 499.80 mg)
potassium asparaginate of 452.00 mg
(in the form of potassium of asparaginate of the gemigidrat of 475.73 mg),
excipients: potassium hydroxide, 10% solution, water for injections.
Description
Transparent, colourless or slightly greenish solution.
Pharmacotherapeutic group
Mineral additives. Other mineral substances.
The ATX A12CX code
the Pharmacological
Pharmacodynamics Ions properties of potassium and magnesium as important intracellular cations get into gear of a number of enzymes, into process of linking of macromolecules with subtsellulyarny elements and into the mechanism of muscular contraction at molecular level. The ratio out of - and intracellular concentration of potassium ions, calcium, sodium and magnesium influences sokratitelny ability of a myocardium. Aspartate as endogenous substance is a carrier of potassium ions and magnesium, has the significant affinity to cells, its salts are exposed to dissociation only in insignificant degree. Thereof ions get into intracellular space in the form of complex connections. Magnesium and potassium aspartate improve metabolism of a myocardium. Insufficient content of potassium and magnesium in an organism increases risk of developing arterial hypertension, atherosclerotic defeat of coronary vessels, disturbances of a heart rhythm, myocardium pathology.
Indications
- for additional therapy in chronic heart diseases (in heart failure, during the postinfraktny period)
- disturbances of a warm rhythm, mainly ventricular arrhythmias
- in a combination with foxglove drugs
the Route of administration and doses
Drug is intended only for intravenous administration. 1-2 ampoules in 5% solution of glucose apply contents to this purpose and enter in the form of intravenous infusion slowly, by drop infusion. If necessary the dose can be repeated in 4-6 hours. Duration of therapy is established individually.
Drug is suitable for combination therapy.
The maximum single dose — 2 ampoules (20 ml) of Panangina®, in case of need perhaps repeated introduction in 4-6 h.
The maximum daily dose – 4 ampoules (40 ml) of Panangina®.
Use in pediatrics
there Are no data on safety and efficiency of medicine at children and teenagers up to 18 years.
Side effects
- emergence of symptoms of a hyperpotassemia / gipermagniyemii at fast administration of drug (the description of symptoms see in the section Overdose)
Contraindications
- sharp and chronic kidney disease
- Addison's disease
- atrioventricular block of the III degree, cardiogenic shock (the ABP & lt, 90
mm Hg)
- the expressed hyperpotassemia
- hypersensitivity to drug components
Medicinal interactions
At simultaneous use of Panangina® with kaliysberegayushchy diuretics and/or APF inhibitors perhaps development of a hyperpotassemia.
Special instructions
Fast administration of drug can cause hyperaemia of the person. It is necessary to be careful when prescribing drug the patient with the diseases which are followed by a hyperpotassemia. At this category of patients it is regularly recommended to investigate concentration of electrolytes in a syvrotka of blood.
Pregnancy and a lactation
use of the drug Panangin® at pregnancy and in the period of a lactation according to indications is possible.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
during use of drug needs to be careful at
control of vehicles or other potentially dangerous mechanisms.
Overdose
At long-term use of drug the cases of overdose were not registered.
Hyperpotassemia symptoms: fatigue, muscle weakness, paresthesias, confusion of consciousness, disorder of function of heart (bradycardia, atrioventricular block, arrhythmia, cardiac arrest)
gipermagniyemiya Symptoms: decrease in neuromuscular excitability, nausea, vomiting, drowsiness, decrease in the ABP. At sharp increase in concentration of an ion of magnesium of blood: oppression of deep tendon jerks, paralysis of breath, lump.
Treatment: drug withdrawal, symptomatic therapy (administration of solution of Calcii chloridum intravenously in a dose of 100 mg/min., in case of need - a hemodialysis).
A form of release and packing
On 10 ml of drug in ampoules from colourless glass with a point for a break.
On 5 ampoules place in plastic blister strip packaging.
On 1 blister strip packaging together with the instruction for medical use in the state and Russian languages place in a box of cardboard.
To Store storage conditions at a temperature from 15 °C to 30 °C.
To store out of children's reach!
3 years
not to use a period of storage after expiry date.
Prescription status
According to the prescription
the Name and the country
of the JSC Gideon Richter manufacturing organization,
1103 Budapest, Dyomryoi St., 19-21, Hungary
the Name and the country of the owner of the registration certificate
of JSC Gideon Richter, Hungary
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products:
Representative office of JSC Gideon Richter in RK
E-mail: info@richter.kz
Phone number: 8-(727) 258-26-22, 8-(727) 258-26-23
Related Products
